Clinical Trials
20 trialsNCT03258567 2026-06-05
Nivolumab in Epstein-Barr Virus (EBV)-Positive Lymphoproliferative Disorders and EBV-Positive Non-HodgkinLymphomas
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT05389423 2026-06-01
Pomalidomide and Dose-Adjusted EPOCH +/- Rituximab for HIV-Associated Lymphomas
National Institutes of Health Clinical Center (CC)
Phase 1 Recruiting
NCT03394365 2026-05-22
ALLELE
Pierre Fabre Medicament
Phase 3 Recruiting
NCT04554914 2026-04-27
A Study to Evaluate Tabelecleucel in Participants With Epstein Barr Virus (EBV) Associated Diseases
Pierre Fabre Medicament
Phase 2 Active not recruiting
NCT06256484 2026-03-11
A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
Atara Biotherapeutics
Phase 1 Terminated
NCT06761677 2026-02-05
A Phase 1b/2 Study of Intravenous Brincidofovir in Patients With Relapsed or Refractory Lymphoma and Relapsed or Refractory Extranodal Natural Killer/T-cell Lymphoma
SymBio Pharmaceuticals
Phase 1/2 Suspended
NCT04664179 2025-12-12
CILESTE
Baylor College of Medicine
Phase 1 Recruiting
NCT01494103 2025-07-11
DOTTI
Baylor College of Medicine
Phase 1 Active not recruiting
NCT00001379 2025-06-19
Treatment and Natural History Study of Lymphomatoid Granulomatosis
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT02580539 2025-05-14
EBV-TCL-01
Maisonneuve-Rosemont Hospital
Phase 1/2 Completed
NCT06224049 2024-03-12
GI-hNeoT-01
BGI, China
Phase EARLY_PHASE1 Recruiting
NCT05775705 2023-03-20
L-DEP Regimen Combined With PD-1 Antibody as Induction Therapy for Epstein-Barr Virus-positive LA-HLH
Beijing Friendship Hospital
Phase 3 Not yet recruiting
NCT01805037 2021-09-01
Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas
Northwestern University
Phase 1/2 Terminated
NCT00058604 2020-01-18
EUCLID
Baylor College of Medicine
Phase 1 Completed
NCT01964755 2019-09-23
Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma
University of Miami
Phase 2 Terminated
NCT02763254 2019-03-26
CIVIC
Cell Medica Ltd
Phase 2 Terminated
NCT01948180 2019-03-13
CITADEL
Cell Medica Ltd
Phase 2 Terminated
NCT02229981 2017-12-07
ABC-102
RedHill Biopharma Limited
Phase 1/2 Withdrawn
NCT00779337 2012-05-22
EPL
Queensland Institute of Medical Research
Phase 1 Completed
NCT01147991 2012-02-28
Vaccine Therapy in Treating Patients With Epstein-Barr Virus-Related Cancer
Cancer Research UK
Phase 1 Completed